26
Participants
Start Date
March 6, 2023
Primary Completion Date
January 31, 2025
Study Completion Date
April 3, 2025
Bemcentinib
Bemcentinib capsules will be administered orally.
Pembrolizumab
Pembrolizumab will be administered as an intravenous (IV) infusion as part of CIT every 3 weeks.
Pemetrexed
Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.
Carboplatin
Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks up to 4 cycles. Each cycle = 21 days.
IFO Regina Elena, Rome
Semmelweis University- Department of Pulmonology, Budapest
Orszagos Koranyi Pulmonologiai Intezet, Budapest
Centre Antoine Lacassagne, Nice
Fejer County St. Gyorgy Hospital, Székesfehérvár
Hospital Universitario Vall d'Hebron, Barcelona
Hospital Universitari Germans Trias i Pujol, Badalona
Icahn School of Medicine at Mount Sinai, New York
General Hospital of Athens Alexandra, Department of the Clinical Therapeutics, Medical Oncology Unit, Athens
Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie, Lublin
IRCCS - Istituto Europeo di Oncologia IEO, Milan
Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore
Duke University Medical Center - Duke Cancer Center, Durham
MD Anderson Cancer Center, Oncology service, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Hospital Universitario Fundacion Jimenez Diaz, Madrid
Hospital Universitario La Paz, Madrid
Mount Sinai Comprehensive Cancer Center, Miami Beach
Tennessee Oncology PLLC, Nashville
Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi, Bologna
University General Hospital of Larissa, Oncology Clinic, Larissa
Hôpital prive du Confluent SAS, Departement d'oncologie, Nantes
Fundacion Instituto Valenciano de Oncologia (FIVO), Valencia
Hospital Clinico Universitario de Valencia, Valencia
Ospedale San Luca, Lucca
University of Chicago, Chicago
MedPolonia Sp z oo, Poznan
Hôpital Europeen Georges Pompidou (HEGP), Service de cancérologie, Paris
UT Southwestern Medical Center, Dallas
Institut Gustave Roussy, Service de médecine, Villejuif
Henry Dunant Hospital Center, 4th Oncology Department, Athens
Sotiria General Hospital of Chest Diseases, 3rd Department of Internal Medicine, Oncology Unit, Athens
Uniwersytecki Szpital Kliniczny w Bialymstoku, II Klinika Chorob Pluc, raka płuca i chorób wewnętrznych, Bialystok
Instytut Centrum Zdrowia Matki Polki (ICZMP), Lodz
Lead Sponsor
BerGenBio ASA
INDUSTRY